These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37400300)

  • 21. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
    Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
    Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Best Practices: Imaging Strategies for Reduced-Dose Chest CT in the Management of Cystic Fibrosis-Related Lung Disease.
    Sheahan KP; Glynn D; Joyce S; Maher MM; Boland F; O'Connor OJ
    AJR Am J Roentgenol; 2021 Aug; 217(2):304-313. PubMed ID: 34076456
    [No Abstract]   [Full Text] [Related]  

  • 23. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
    Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
    Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy.
    Brambilla M; Matheoud R; Margiotta-Casaluci G; Cannillo B; D'Alessio A; Siciliano C; Carriero A; Gaidano G
    Br J Radiol; 2023 Sep; 96(1149):20230106. PubMed ID: 37493259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients undergoing multiphase CT scans and receiving a cumulative effective dose of ≥ 100 mSv in a single episode of care.
    Brambilla M; Cannillo B; D'Alessio A; Matheoud R; Agliata MF; Carriero A
    Eur Radiol; 2021 Jul; 31(7):4452-4458. PubMed ID: 33449187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
    Albright JC; Houck AP; Pettit RS
    Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation exposure from medical imaging in dialyzed patients undergoing renal pre-transplant evaluation.
    De Mauri A; Matheoud R; Carriero A; Lizio D; Chiarinotti D; Brambilla M
    J Nephrol; 2017 Feb; 30(1):141-146. PubMed ID: 26936613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.
    Vincken S; Verbanck S; Braun S; Buyck N; Knoop C; Vanderhelst E
    Acta Clin Belg; 2023 Aug; 78(4):280-284. PubMed ID: 36415912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis.
    Van Citters AD; Aliaj E; Alvarez JA; Brown CD; Cary J; Cravens R; Frederick CA; Georgiopoulos AM; Goss CH; Kazmerski TM; King JR; Lawrence M; Lovell C; Roman C; Tillman L; Yu E
    J Cyst Fibros; 2024 Jul; ():. PubMed ID: 39060182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of low-dose protocols for thin-section CT assessment of cystic fibrosis in pediatric patients.
    O'Connor OJ; Vandeleur M; McGarrigle AM; Moore N; McWilliams SR; McSweeney SE; O'Neill M; Ni Chroinin M; Maher MM
    Radiology; 2010 Dec; 257(3):820-9. PubMed ID: 20876388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
    Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
    J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of CFTR modulators on structural lung disease in cystic fibrosis.
    Mok LC; Garcia-Uceda A; Cooper MN; Kemner-Van De Corput M; De Bruijne M; Feyaerts N; Rosenow T; De Boeck K; Stick S; Tiddens HAWM
    Front Pharmacol; 2023; 14():1147348. PubMed ID: 37113757
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels.
    Bramilla M; Berton L; Balzano RF; Cannillo B; Carriero A; Chauvie S; Gallo T; Cornacchia S; Cutaia C; D'Alessio A; Emanuele R; Fonio P; Matheoud R; Stasi M; Talenti A; Rampado O
    Eur Radiol; 2024 Jul; 34(7):4475-4483. PubMed ID: 38127075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Lynch DA; Taylor-Cousar JL
    Ann Am Thorac Soc; 2022 Jan; 19(1):12-19. PubMed ID: 34436985
    [No Abstract]   [Full Text] [Related]  

  • 37. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
    Tabori H; Schneider J; Lüth S; Zagoya C; Barucha A; Lehmann T; Kauf E; Barth A; Mainz JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of model-based iterative reconstruction in cystic fibrosis assessment using CT.
    Lin S; Lin M; Lau KK
    Clin Radiol; 2019 Jul; 74(7):569.e19-569.e27. PubMed ID: 31036312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients undergoing recurrent CT scans: assessing the magnitude.
    Rehani MM; Yang K; Melick ER; Heil J; Šalát D; Sensakovic WF; Liu B
    Eur Radiol; 2020 Apr; 30(4):1828-1836. PubMed ID: 31792585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
    Zemanick ET; Konstan MW; VanDevanter DR; Rowe SM; Clancy JP; Odem-Davis K; Skalland M; Mayer-Hamblett N
    J Cyst Fibros; 2021 Nov; 20(6):965-971. PubMed ID: 33573995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.